

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5643770

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
ESBATECH, A NOVARTIS COMPANY LLC		05/08/2019
RECEIVING PARTY DATA		
Name:	NOVARTIS AG	
Street Address:	LICHTSTRASSE 35	
City:	BASEL	
State/Country:	SWITZERLAND	
Postal Code:	4056	
PROPERTY NUMBERS Total: 5		
Property Type	Number	
Application Number:	61133212	
Patent Number:	8349322	
Patent Number:	9090684	
Patent Number:	9873737	
Application Number:	15814784	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	stephanie.geis@novartis.com	
Correspondent Name:	STEPHANIE GEIS	
Address Line 1:	700 MAIN STREET	
Address Line 2:	NIBR	
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02139	
ATTORNEY DOCKET NUMBER:	PAT903793-US	
NAME OF SUBMITTER:	STEPHANIE GEIS	
SIGNATURE:	/Stephanie Geis/	
DATE SIGNED:	07/30/2019	
Total Attachments: 25		
source=[Untitled]#page1.tif		

source=[Untitled]#page2.tif
source=[Untitled]#page3.tif
source=[Untitled]#page4.tif
source=[Untitled]#page5.tif
source=[Untitled]#page6.tif
source=[Untitled]#page7.tif
source=[Untitled]#page8.tif
source=[Untitled]#page9.tif
source=[Untitled]#page10.tif
source=[Untitled]#page11.tif
source=[Untitled]#page12.tif
source=[Untitled]#page13.tif
source=[Untitled]#page14.tif
source=[Untitled]#page15.tif
source=[Untitled]#page16.tif
source=[Untitled]#page17.tif
source=[Untitled]#page18.tif
source=[Untitled]#page19.tif
source=[Untitled]#page20.tif
source=[Untitled]#page21.tif
source=[Untitled]#page22.tif
source=[Untitled]#page23.tif
source=[Untitled]#page24.tif
source=[Untitled]#page25.tif

ASSIGNMENT

This Assignment Agreement is entered into by and between ESBATech, a Novartis Company LLC (hereinafter "ESBATech") formerly of Wagistrasse 12, 8952 Schlieren, Switzerland (see attached Commercial Register for former names and current domicile information), a company organized under the laws of Switzerland, and NOVARTIS AG, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, ESBATech does hereby sell, assign and transfer to NOVARTIS AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional and non-provisional patent applications and patents entitled

SEE ATTACHED SCHEDULE

(2) the patents and applications identified in paragraph (1), and all patents and applications claiming priority from such patents and applications, directly or indirectly, including all national stages of any international patent and patent applications;

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the patents and applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the patents and applications referred to in paragraphs (1), (2), and (3) or from any patent or application from which any of the patents and applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed ESBATech if this sale, assignment and transfer had not been made.

ESBATech hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

ESBATech hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 8 day of May, 2019.

ESBATech, a Novartis Company LLC

BY

Witness

Print Name:

Monika Renz

Lichtstrasse 35
4056 Basel
Switzerland

Witness

Print Name:

Elena Brugnera
Lichtstrasse 35
4056 Basel
Switzerland

BY

Witness

Print Name:

Monika Renz

Lichtstrasse 35
4056 Basel
Switzerland

Witness

Print Name:


Elena Brugnera
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 9 day of May, 2019.


NOVARTIS AG

BY 

Ian James Hiscock
Witness Authorized Signatory
Print Name:


Witness
Print Name: ANJA W. B. B. B. Lichtstrasse 35
4056 Basel
Switzerland


Witness
Elena Brugnara
Lichtstrasse 35
4056 Basel
Switzerland

BY 

Isabelle Schubert Santana
Witness Authorized Signatory
Print Name:


Witness
Print Name: Monica Reppe

Lichtstrasse 35
4056 Basel
Switzerland


Elena Brugnara
Lichtstrasse 35
4056 Basel
Switzerland

SCHEDULE

Novartis reference	Country	Filing Date	Filing Number
PAT903763-AR-NP	AR	22 Dez 2010	P100104885
PAT903763-AU-PCT	AU	21 Dez 2010	2010335950
PAT903763-AU-PCTD	AU	12 Nov 2014	2014262201
PAT903763-BR-PCT	BR	21 Dez 2010	112012017051-1
PAT903763-CA-PCT	CA	21 Dez 2010	2777527
PAT903763-CL-PCT	CL	21 Dez 2010	2012-1696
PAT903763-CN-PCT	CN	21 Dez 2010	201080058509.1
PAT903763-CN-PCTD	CN	29 Okt 2018	201811275095.2
PAT903763-EG-PCT	EG	21 Dez 2010	552/2012
PAT903763-EP-EPT	EP	21 Dez 2010	10798948.5
PAT903763-EP-ETD	EP	05 Nov 2018	18204324.0
PAT903763-GC-NP	GC	22 Dez 2010	GC 2010-17442
PAT903763-HK-FPR	HK	18 Mär 2013	13103304.0
PAT903763-IN-PCT	IN	21 Dez 2010	774/MUMNP/2012
PAT903763-JP-PCT	JP	21 Dez 2010	2012-545039
PAT903763-JP-PCTD	JP	21 Apr 2015	2015-86411
PAT903763-JP-PCTD02	JP	23 Feb 2016	2016-031635
PAT903763-JP-PCTD03	JP	05 Apr 2017	2017-75022
PAT903763-JP-PCTD04	JP	12 Apr 2019	2019-076216
PAT903763-KR-PCT	KR	21 Dez 2010	2012-7013364
PAT903763-KR-PCTD	KR	23 Mär 2017	2017-7008037
PAT903763-KR-PCTD02	KR	11 Jul 2017	2017-7019170
PAT903763-MX-PCT	MX	21 Dez 2010	MXA2012005345
PAT903763-MX-PCTD	MX	18 Aug 2015	MX/A/2015/010691
PAT903763-PH-PCT	PH	21 Dez 2010	1-2012-500794
PAT903763-RU-PCT	RU	21 Dez 2010	2012130945
PAT903763-TW-DIV	TW	16 Feb 2016	105104469
PAT903763-TW-DIV02	TW	26 Mär 2019	108110520
PAT903763-TW-NP	TW	22 Dez 2010	99145201
PAT903763-US-DIV	US	19 Jun 2014	14/308936
PAT903763-US-DIV02	US	21 Sep 2017	15/711181
PAT903763-US-NP	US	21 Dez 2010	12/973968
PAT903763-US-PSP	US	23 Dez 2009	61/289446
PAT903763-UY-NP	UY	22 Dez 2010	33.154
PAT903763-WO-PCT	WO	21 Dez 2010	PCT/CH10/000326
PAT903763-ZA-PCT	ZA	21 Dez 2010	2012/02299
PAT903763-ZA-PCTD	ZA	24 Mär 2014	2014/02145
PAT903763-ZA-PCTD02	ZA	22 Sep 2017	2017/06443
PAT903769-AU-PCT	AU	11 Apr 2003	2003216640
PAT903769-CA-PCT	CA	11 Apr 2003	2521382
PAT903769-EP-EPT	EP	11 Apr 2003	03712550.7
PAT903769-US-PCT	US	11 Apr 2003	10/552219
PAT903769-US-PCTD	US	11 Okt 2010	12/901785
PAT903769-WO-PCT	WO	11 Apr 2003	PCT/IB03/001452
PAT903772-AT-EPT	AT	21 Mai 2003	03732434.0
PAT903772-AT-ETD	AT	21 Mai 2003	10009857.3
PAT903772-AU-PCT	AU	21 Mai 2003	2003238370
PAT903772-AU-PCTD	AU	24 Jun 2010	2010202634
PAT903772-AU-PCTD02	AU	01 Aug 2012	2012211497
PAT903772-AU-PCTD03	AU	10 Apr 2013	2013203288
PAT903772-AU-PCTD04	AU	10 Apr 2013	2013203285

Novartis reference	Country	Filing Date	Filing Number
PAT903772-AU-PCTD05	AU	06 Mai 2015	2015202410
PAT903772-BE-EPT	BE	21 Mai 2003	03732434.0
PAT903772-BE-ETD	BE	21 Mai 2003	10009857.3
PAT903772-BG-EPT	BG	21 Mai 2003	03732434.0
PAT903772-BG-ETD	BG	21 Mai 2003	10009857.3
PAT903772-CA-PCT	CA	21 Mai 2003	2483285
PAT903772-CA-PCTD	CA	16 Okt 2014	2867542
PAT903772-CH-EPT	CH	21 Mai 2003	03732434.0
PAT903772-CH-ETD	CH	21 Mai 2003	10009857.3
PAT903772-CH-ETD02	CH	21 Mai 2003	10010455.3
PAT903772-CN-PCT	CN	21 Mai 2003	03814626.6
PAT903772-CN-PCTD	CN	07 Dez 2010	2010105757861
PAT903772-CN-PCTD02	CN	23 Jan 2014	201410031953.4
PAT903772-CN-PCTD03	CN	21 Okt 2015	201510685456.0
PAT903772-CY-EPT	CY	21 Mai 2003	03732434.0
PAT903772-CZ-EPT	CZ	21 Mai 2003	03732434.0
PAT903772-CZ-ETD	CZ	21 Mai 2003	10009857.3
PAT903772-DE-EPT	DE	21 Mai 2003	03732434.0
PAT903772-DE-ETD	DE	21 Mai 2003	10009857.3
PAT903772-DE-ETD02	DE	21 Mai 2003	10010455.3
PAT903772-DK-EPT	DK	21 Mai 2003	03732434.0
PAT903772-DK-ETD	DK	21 Mai 2003	10009857.3
PAT903772-EE-EPT	EE	21 Mai 2003	03732434.0
PAT903772-EE-ETD	EE	21 Mai 2003	10009857.3
PAT903772-EP-EPT	EP	21 Mai 2003	03732434.0
PAT903772-EP-ETD	EP	21 Mai 2003	10009857.3
PAT903772-EP-ETD02	EP	21 Mai 2003	10010455.3
PAT903772-EP-ETD03	EP	25 Mär 2015	15160739.7
PAT903772-ES-EPT	ES	21 Mai 2003	03732434.0
PAT903772-ES-ETD	ES	21 Mai 2003	10009857.3
PAT903772-ES-ETD02	ES	21 Mai 2003	10010455.3
PAT903772-FI-EPT	FI	21 Mai 2003	03732434.0
PAT903772-FI-ETD	FI	21 Mai 2003	10009857.3
PAT903772-FR-EPT	FR	21 Mai 2003	03732434.0
PAT903772-FR-ETD	FR	21 Mai 2003	10009857.3
PAT903772-FR-ETD02	FR	21 Mai 2003	10010455.3
PAT903772-GB-EPT	GB	21 Mai 2003	03732434.0
PAT903772-GB-ETD	GB	21 Mai 2003	10009857.3
PAT903772-GB-ETD02	GB	21 Mai 2003	10010455.3
PAT903772-GR-EPT	GR	21 Mai 2003	03732434.0
PAT903772-GR-ETD	GR	21 Mai 2003	10009857.3
PAT903772-HK-FPD	HK	16 Mai 2016	16105597.8
PAT903772-HK-FPR	HK	09 Jun 2011	11105827.5
PAT903772-HK-FPR02	HK	13 Mai 2005	05104060.2
PAT903772-HK-FPR03	HK	23 Jun 2011	11106519.6
PAT903772-HU-EPT	HU	21 Mai 2003	03732434.0
PAT903772-HU-ETD	HU	21 Mai 2003	10009857.3
PAT903772-IE-EPT	IE	21 Mai 2003	03732434.0
PAT903772-IE-ETD	IE	21 Mai 2003	10009857.3
PAT903772-IN-PCT	IN	21 Mai 2003	3470/DELNP/2004
PAT903772-IN-PCTD	IN	27 Jan 2017	201718003114
PAT903772-IT-EPT	IT	21 Mai 2003	03732434.0
PAT903772-IT-ETD	IT	21 Mai 2003	10009857.3

Novartis reference	Country	Filing Date	Filing Number
PAT903772-IT-ETD02	IT	21 Mai 2003	10010455.3
PAT903772-JP-PCT	JP	21 Mai 2003	2004-506369
PAT903772-JP-PCTD	JP	17 Mär 2010	2010-060713
PAT903772-JP-PCTD02	JP	28 Aug 2012	2012-187518
PAT903772-JP-PCTD03	JP	04 Feb 2013	2013-19425
PAT903772-JP-PCTD04	JP	19 Sep 2013	2013-193935
PAT903772-JP-PCTD05	JP	19 Aug 2015	2015-161600
PAT903772-JP-PCTD06	JP	19 Aug 2015	2015-161601
PAT903772-JP-PCTD07	JP	24 Aug 2017	2017-161036
PAT903772-JP-PCTD08	JP	23 Jan 2019	2019-009288
PAT903772-LU-EPT	LU	21 Mai 2003	03732434.0
PAT903772-LU-ETD	LU	21 Mai 2003	10009857.3
PAT903772-MC-EPT	MC	21 Mai 2003	03732434.0
PAT903772-NL-EPT	NL	21 Mai 2003	03732434.0
PAT903772-NL-ETD	NL	21 Mai 2003	10009857.3
PAT903772-NZ-PCT	NZ	21 Mai 2003	PCT/EP03/005324
PAT903772-PT-EPT	PT	21 Mai 2003	03732434.0
PAT903772-PT-ETD	PT	21 Mai 2003	10009857.3
PAT903772-RO-EPT	RO	21 Mai 2003	03732434.0
PAT903772-RO-ETD	RO	21 Mai 2003	10009857.3
PAT903772-SE-EPT	SE	21 Mai 2003	03732434.0
PAT903772-SE-ETD	SE	21 Mai 2003	10009857.3
PAT903772-SI-EPT	SI	21 Mai 2003	03732434.0
PAT903772-SI-ETD	SI	21 Mai 2003	10009857.3
PAT903772-SK-EPT	SK	21 Mai 2003	03732434.0
PAT903772-SK-ETD	SK	21 Mai 2003	10009857.3
PAT903772-TR-EPT	TR	21 Mai 2003	03732434.0
PAT903772-TR-ETD	TR	21 Mai 2003	10009857.3
PAT903772-US-PCT	US	21 Mai 2003	10/515241
PAT903772-US-PCTD	US	26 Aug 2014	14/469276
PAT903772-US-PCTD02	US	01 Nov 2016	15/340195
PAT903772-US-PCTD03	US	30 Okt 2018	16/175002
PAT903772-WO-PCT	WO	21 Mai 2003	PCT/EP03/005324
PAT903779-US-PSP	US	22 Mai 2002	60/382774
PAT903779-WO-PCT	WO	21 Mai 2003	EP2003005325
PAT903781-AT-EPT	AT	25 Jun 2008	08757277.2
PAT903781-AU-PCT	AU	25 Jun 2008	2008267733
PAT903781-BE-EPT	BE	25 Jun 2008	08757277.2
PAT903781-BG-EPT	BG	25 Jun 2008	08757277.2
PAT903781-BR-PCT	BR	25 Jun 2008	PI0813287-9
PAT903781-CA-PCT	CA	25 Jun 2008	2689064
PAT903781-CH-EPT	CH	25 Jun 2008	08757277.2
PAT903781-CN-PCT	CN	25 Jun 2008	200880021937X
PAT903781-CZ-EPT	CZ	25 Jun 2008	08757277.2
PAT903781-DE-EPT	DE	25 Jun 2008	08757277.2
PAT903781-DK-EPT	DK	25 Jun 2008	08757277.2
PAT903781-EG-PCT	EG	25 Jun 2008	1742/2009
PAT903781-EP-EPT	EP	25 Jun 2008	08757277.2
PAT903781-ES-EPT	ES	25 Jun 2008	08757277.2
PAT903781-FI-EPT	FI	25 Jun 2008	08757277.2
PAT903781-FR-EPT	FR	25 Jun 2008	08757277.2
PAT903781-GB-EPT	GB	25 Jun 2008	08757277.2
PAT903781-GR-EPT	GR	25 Jun 2008	08757277.2

Novartis reference	Country	Filing Date	Filing Number
PAT903781-HK-FPR	HK	25 Jun 2008	10103507.8
PAT903781-HK-FPR02	HK	25 Jun 2008	HK FX
PAT903781-HU-EPT	HU	25 Jun 2008	08757277.2
PAT903781-IE-EPT	IE	25 Jun 2008	08757277.2
PAT903781-IL-PCT	IL	25 Jun 2008	202352
PAT903781-IN-PCT	IN	25 Jun 2008	7908DELNP09
PAT903781-IT-EPT	IT	25 Jun 2008	08757277.2
PAT903781-JP-PCT	JP	25 Jun 2008	2010-513600
PAT903781-JP-PCTD	JP	17 Okt 2013	2013-216065
PAT903781-KR-PCT	KR	25 Jun 2008	10-2009-7027050
PAT903781-LT-EPT	LT	25 Jun 2008	08757277.2
PAT903781-LU-EPT	LU	25 Jun 2008	08757277.2
PAT903781-LV-EPT	LV	25 Jun 2008	08757277.2
PAT903781-MX-PCT	MX	25 Jun 2008	2009/013327
PAT903781-NL-EPT	NL	25 Jun 2008	08757277.2
PAT903781-NO-EPT	NO	25 Jun 2008	08757277.2
PAT903781-NZ-PCT	NZ	25 Jun 2008	581470
PAT903781-PH-PCT	PH	25 Jun 2008	1-2009-502232
PAT903781-PL-EPT	PL	25 Jun 2008	08757277.2
PAT903781-PT-EPT	PT	25 Jun 2008	08757277.2
PAT903781-RO-EPT	RO	25 Jun 2008	08757277.2
PAT903781-RU-PCT	RU	25 Jun 2008	2010102064
PAT903781-RU-PCTD	RU	15 Okt 2013	2013146000
PAT903781-SE-EPT	SE	25 Jun 2008	08757277.2
PAT903781-SI-EPT	SI	25 Jun 2008	08757277.2
PAT903781-SK-EPT	SK	25 Jun 2008	08757277.2
PAT903781-TR-EPT	TR	25 Jun 2008	08757277.2
PAT903781-US-NP	US	25 Jun 2008	12/145749
PAT903781-US-PSP	US	25 Jun 2007	60/937112
PAT903781-US-PSP02	US	12 Mär 2008	61/069057
PAT903781-WO-PCT	WO	25 Jun 2008	PCT/CH08/000284
PAT903781-ZA-PCT	ZA	25 Jun 2008	2009/08314
PAT903782-AU-PCT	AU	12 Mär 2008	2008226067
PAT903782-CA-PCT	CA	12 Mär 2008	2680564
PAT903782-CN-PCT	CN	12 Mär 2008	200880007946.3
PAT903782-CN-PCTD	CN	10 Mai 2013	201310170015.8
PAT903782-EP-ETD	EP	08 Mär 2017	17159837.8
PAT903782-HK-FPD	HK	06 Feb 2018	18101800.8
PAT903782-HK-FPR	HK	21 Apr 2010	10103877.0
PAT903782-IL-PCT	IL	12 Mär 2008	200710
PAT903782-IN-PCT	IN	12 Mär 2008	5758DELNP2009
PAT903782-JP-PCT	JP	12 Mär 2008	2009-553071
PAT903782-NZ-PCT	NZ	12 Mär 2008	579594
PAT903782-RU-PCT	RU	12 Mär 2008	2009137582
PAT903782-RU-PCTD	RU	03 Jul 2014	2014127308
PAT903782-US-CNT	US	23 Aug 2012	13/592885
PAT903782-US-CNT02	US	29 Mär 2018	15/939803
PAT903782-US-PCT	US	12 Mär 2008	12/530756
PAT903782-US-PSP	US	12 Mär 2007	60/906365
PAT903782-WO-PCT	WO	12 Mär 2008	PCT/EP08/001958
PAT903783-AT-EPT	AT	25 Jun 2008	08757278.0
PAT903783-AU-PCT	AU	25 Jun 2008	2008267734
PAT903783-BE-EPT	BE	25 Jun 2008	08757278.0

Novartis reference	Country	Filing Date	Filing Number
PAT903783-BG-EPT	BG	25 Jun 2008	08757278.0
PAT903783-BR-PCT	BR	25 Jun 2008	PI0813645-9
PAT903783-CA-PCT	CA	25 Jun 2008	2689941
PAT903783-CH-EPT	CH	25 Jun 2008	08757278.0
PAT903783-CN-PCT	CN	25 Jun 2008	2008800218894
PAT903783-CN-PCTD	CN	31 Aug 2012	201210317160.X
PAT903783-CN-PCTD02	CN	29 Aug 2013	201310383003.3
PAT903783-CN-PCTD03	CN	25 Jun 2015	201510357753.2
PAT903783-CN-PCTD04	CN	27 Sep 2016	201610852278.0
PAT903783-CZ-EPT	CZ	25 Jun 2008	08757278.0
PAT903783-DE-EPT	DE	25 Jun 2008	08757278.0
PAT903783-DK-EPT	DK	25 Jun 2008	08757278.0
PAT903783-EG-PCT	EG	25 Jun 2008	1743/2009
PAT903783-EP-EPT	EP	25 Jun 2008	08757278.0
PAT903783-ES-EPT	ES	25 Jun 2008	08757278.0
PAT903783-FI-EPT	FI	25 Jun 2008	08757278.0
PAT903783-FR-EPT	FR	25 Jun 2008	08757278.0
PAT903783-GB-EPT	GB	25 Jun 2008	08757278.0
PAT903783-GR-EPT	GR	25 Jun 2008	08757278.0
PAT903783-HK-FPR	HK	09 Apr 2010	10103501.4
PAT903783-HR-EPT	HR	25 Jun 2008	08757278.0
PAT903783-HU-EPT	HU	25 Jun 2008	08757278.0
PAT903783-IE-EPT	IE	25 Jun 2008	08757278.0
PAT903783-IL-PCT	IL	25 Jun 2008	202360
PAT903783-IN-PCT	IN	25 Jun 2008	8072DELNP09
PAT903783-IT-EPT	IT	25 Jun 2008	08757278.0
PAT903783-JP-PCT	JP	25 Jun 2008	2010-513601
PAT903783-JP-PCTD	JP	03 Sep 2014	2014-178667
PAT903783-JP-PCTD02	JP	12 Apr 2017	2017-079036
PAT903783-KR-PCT	KR	25 Jun 2008	2009-7027049
PAT903783-LT-EPT	LT	25 Jun 2008	08757278.0
PAT903783-LU-EPT	LU	25 Jun 2008	08757278.0
PAT903783-LV-EPT	LV	25 Jun 2008	08757278.0
PAT903783-MX-PCT	MX	25 Jun 2008	2009/013328
PAT903783-MX-PCTD	MX	25 Jun 2008	MX/a/2012/001899
PAT903783-MX-PCTD02	MX	16 Apr 2014	MX/a/2014/004708
PAT903783-NL-EPT	NL	25 Jun 2008	08757278.0
PAT903783-NO-EPT	NO	25 Jun 2008	08757278.0
PAT903783-NZ-PCT	NZ	25 Jun 2008	581468
PAT903783-NZ-PCTD	NZ	25 Jun 2008	601946
PAT903783-NZ-PCTD02	NZ	26 Jul 2013	613649
PAT903783-NZ-PCTD03	NZ	23 Jan 2014	620261
PAT903783-NZ-PCTD04	NZ	30 Mai 2014	625731
PAT903783-NZ-PCTD05	NZ	20 Jul 2015	710254
PAT903783-NZ-PCTD06	NZ	09 Feb 2017	728954
PAT903783-NZ-PCTD07	NZ	18 Sep 2018	746347
PAT903783-PH-PCT	PH	25 Jun 2008	1-2009-502285
PAT903783-PL-EPT	PL	25 Jun 2008	08757278.0
PAT903783-PT-EPT	PT	25 Jun 2008	08757278.0
PAT903783-RO-EPT	RO	25 Jun 2008	08757278.0
PAT903783-RU-PCT	RU	25 Jun 2008	2010102065
PAT903783-RU-PCTD	RU	22 Okt 2014	2014142680
PAT903783-SE-EPT	SE	25 Jun 2008	08757278.0

Novartis reference	Country	Filing Date	Filing Number
PAT903783-SI-EPT	SI	25 Jun 2008	08757278.0
PAT903783-SK-EPT	SK	25 Jun 2008	08757278.0
PAT903783-TR-EPT	TR	25 Jun 2008	08757278.0
PAT903783-US-DIV	US	12 Sep 2017	15/701923
PAT903783-US-NP	US	25 Jun 2008	12/145600
PAT903783-US-PSP	US	12 Mär 2008	61/069056
PAT903783-WO-PCT	WO	25 Jun 2008	PCT/CH08/000285
PAT903783-ZA-PCT	ZA	25 Jun 2008	2009/08384
PAT903784-AT-EPT	AT	25 Jun 2009	09768695.0
PAT903784-AU-PCT	AU	25 Jun 2009	2009264567
PAT903784-AU-PCTD	AU	08 Apr 2013	2013203004
PAT903784-AU-PCTD02	AU	11 Jul 2014	2014203813
PAT903784-AU-PCTD03	AU	18 Feb 2016	2016201023
PAT903784-AU-PCTD04	AU	25 Jan 2018	2018200640
PAT903784-BE-EPT	BE	25 Jun 2009	09768695.0
PAT903784-BG-EPT	BG	25 Jun 2009	09768695.0
PAT903784-BR-PCT	BR	25 Jun 2009	PI0914663-6
PAT903784-CA-PCT	CA	25 Jun 2009	2728004
PAT903784-CH-EPT	CH	25 Jun 2009	09768695.0
PAT903784-CL-PCT	CL	25 Jun 2009	2010-1539
PAT903784-CN-PCT	CN	25 Jun 2009	200980124312.0
PAT903784-CN-PCTD	CN	08 Mai 2014	201410191675.9
PAT903784-CN-PCTD02	CN	27 Mär 2017	201710186530.3
PAT903784-CZ-EPT	CZ	25 Jun 2009	09768695.0
PAT903784-DE-EPT	DE	25 Jun 2009	09768695.0
PAT903784-DK-EPT	DK	25 Jun 2009	09768695.0
PAT903784-EG-PCT	EG	25 Jun 2009	2023/2010
PAT903784-EP-EPT	EP	25 Jun 2009	09768695.0
PAT903784-EP-ETD	EP	31 Mär 2014	14162664.8
PAT903784-ES-EPT	ES	25 Jun 2009	09768695.0
PAT903784-FI-EPT	FI	25 Jun 2009	09768695.0
PAT903784-FR-EPT	FR	25 Jun 2009	09768695.0
PAT903784-GB-EPT	GB	25 Jun 2009	09768695.0
PAT903784-GR-EPT	GR	25 Jun 2009	09768695.0
PAT903784-HK-FPD	HK	24 Jul 2014	14107549.6
PAT903784-HK-FPR	HK	18 Mai 2011	11104915.1
PAT903784-HU-EPT	HU	25 Jun 2009	09768695.0
PAT903784-IE-EPT	IE	25 Jun 2009	09768695.0
PAT903784-IN-PCT	IN	25 Jun 2009	4926/KOLNP/2010
PAT903784-IT-EPT	IT	25 Jun 2009	09768695.0
PAT903784-JP-PCT	JP	25 Jun 2009	2011-515051
PAT903784-JP-PCTD	JP	18 Mär 2015	2015-054497
PAT903784-JP-PCTD02	JP	27 Apr 2016	2016-88845
PAT903784-JP-PCTD03	JP	31 Jul 2017	2017-148091
PAT903784-JP-PCTD04	JP	01 Feb 2019	2019-016882
PAT903784-KR-PCT	KR	25 Jun 2009	2011-7001962
PAT903784-KR-PCTD	KR	12 Feb 2016	2016-7003710
PAT903784-KR-PCTD02	KR	05 Jul 2016	2016-7018056
PAT903784-KR-PCTD03	KR	20 Jul 2018	2018-7021025
PAT903784-MX-PCT	MX	25 Jun 2009	2011/000052
PAT903784-MX-PCTD	MX	30 Apr 2013	MX/a/2013/004869
PAT903784-MX-PCTD02	MX	27 Jan 2017	MX/A/2017/001250
PAT903784-NL-EPT	NL	25 Jun 2009	09768695.0

Novartis reference	Country	Filing Date	Filing Number
PAT903784-NO-EPT	NO	25 Jun 2009	09768695.0
PAT903784-PH-PCT	PH	25 Jun 2009	1-2010-502918
PAT903784-PH-PCTD	PH	25 Okt 2013	1-2013-502219
PAT903784-PH-PCTD02	PH	13 Aug 2018	1-2018-501715
PAT903784-PL-EPT	PL	25 Jun 2009	09768695.0
PAT903784-PT-EPT	PT	25 Jun 2009	09768695.0
PAT903784-RO-EPT	RO	25 Jun 2009	09768695.0
PAT903784-RU-PCT	RU	25 Jun 2009	2011102557
PAT903784-RU-PCTD	RU	24 Mär 2014	2014111173
PAT903784-RU-PCTD02	RU	19 Mär 2018	2018109506
PAT903784-SE-EPT	SE	25 Jun 2009	09768695.0
PAT903784-SI-EPT	SI	25 Jun 2009	09768695.0
PAT903784-SK-EPT	SK	25 Jun 2009	09768695.0
PAT903784-TR-EPT	TR	25 Jun 2009	09768695.0
PAT903784-US-PCT	US	25 Jun 2009	13/000309
PAT903784-US-PCTD	US	14 Sep 2012	13/616214
PAT903784-US-PCTD02	US	12 Feb 2014	14/179141
PAT903784-US-PCTD03	US	10 Dez 2015	14/965488
PAT903784-US-PCTD04	US	18 Dez 2017	15/844984
PAT903784-US-PSP	US	25 Jun 2008	61/075697
PAT903784-US-PSP02	US	24 Feb 2009	61/155041
PAT903784-WO-PCT	WO	25 Jun 2009	PCT/CH09/000222
PAT903784-ZA-PCT	ZA	25 Jun 2009	2010/08592
PAT903784-ZA-PCTD	ZA	21 Nov 2013	2013/08755
PAT903784-ZA-PCTD02	ZA	11 Mai 2015	2015/03267
PAT903784-ZA-PCTD03	ZA	09 Mai 2016	2016/03106
PAT903784-ZA-PCTD04	ZA	08 Mai 2018	2018/02994
PAT903785-AT-EPT	AT	25 Jun 2009	09768694.3
PAT903785-AU-PCT	AU	25 Jun 2009	2009264566
PAT903785-AU-PCTD	AU	10 Apr 2013	2013203477
PAT903785-AU-PCTD02	AU	08 Mai 2015	2015202499
PAT903785-BE-EPT	BE	25 Jun 2009	09768694.3
PAT903785-BG-EPT	BG	25 Jun 2009	09768694.3
PAT903785-BR-PCT	BR	25 Jun 2009	PI0914666-0
PAT903785-CA-PCT	CA	25 Jun 2009	2728829
PAT903785-CH-EPT	CH	25 Jun 2009	09768694.3
PAT903785-CN-PCT	CN	25 Jun 2009	200980123815.6
PAT903785-CN-PCTD	CN	30 Dez 2015	201511018105.0
PAT903785-CY-EPT	CY	25 Jun 2009	09768694.3
PAT903785-CZ-EPT	CZ	25 Jun 2009	09768694.3
PAT903785-DE-EPT	DE	25 Jun 2009	09768694.3
PAT903785-DK-EPT	DK	25 Jun 2009	09768694.3
PAT903785-EE-EPT	EE	25 Jun 2009	09768694.3
PAT903785-EP-EPT	EP	25 Jun 2009	09768694.3
PAT903785-EP-ETD	EP	21 Mär 2017	17161990.1
PAT903785-ES-EPT	ES	25 Jun 2009	09768694.3
PAT903785-FI-EPT	FI	25 Jun 2009	09768694.3
PAT903785-FR-EPT	FR	25 Jun 2009	09768694.3
PAT903785-GB-EPT	GB	25 Jun 2009	09768694.3
PAT903785-GR-EPT	GR	25 Jun 2009	09768694.3
PAT903785-HR-EPT	HR	25 Jun 2009	09768694.3
PAT903785-HU-EPT	HU	25 Jun 2009	09768694.3
PAT903785-IE-EPT	IE	25 Jun 2009	09768694.3

Novartis reference	Country	Filing Date	Filing Number
PAT903785-IN-PCT	IN	25 Jun 2009	4904KOLNP2010
PAT903785-IS-EPT	IS	25 Jun 2009	09768694.3
PAT903785-IT-EPT	IT	25 Jun 2009	09768694.3
PAT903785-JP-PCT	JP	25 Jun 2009	2011-515050
PAT903785-JP-PCTD	JP	18 Mär 2014	2014-54856
PAT903785-JP-PCTD02	JP	06 Apr 2016	2016-76318
PAT903785-KR-PCT	KR	25 Jun 2009	2011-7001959
PAT903785-KR-PCTD	KR	27 Jun 2016	2016-7017202
PAT903785-LT-EPT	LT	25 Jun 2009	09768694.3
PAT903785-LU-EPT	LU	25 Jun 2009	09768694.3
PAT903785-LV-EPT	LV	25 Jun 2009	09768694.3
PAT903785-MC-EPT	MC	25 Jun 2009	09768694.3
PAT903785-MK-EPT	MK	25 Jun 2009	09768694.3
PAT903785-MT-EPT	MT	25 Jun 2009	09768694.3
PAT903785-MX-PCT	MX	25 Jun 2009	2011/000074
PAT903785-MX-PCTD	MX	11 Okt 2013	MX/a/2013/011865
PAT903785-NL-EPT	NL	25 Jun 2009	09768694.3
PAT903785-NO-EPT	NO	25 Jun 2009	09768694.3
PAT903785-PL-EPT	PL	25 Jun 2009	09768694.3
PAT903785-PT-EPT	PT	25 Jun 2009	09768694.3
PAT903785-RO-EPT	RO	25 Jun 2009	09768694.3
PAT903785-RU-PCT	RU	25 Jun 2009	2011102548
PAT903785-RU-PCTD	RU	10 Feb 2014	2014104577
PAT903785-RU-PCTD02	RU	05 Apr 2018	2018112257
PAT903785-SE-EPT	SE	25 Jun 2009	09768694.3
PAT903785-SI-EPT	SI	25 Jun 2009	09768694.3
PAT903785-SK-EPT	SK	25 Jun 2009	09768694.3
PAT903785-TR-EPT	TR	25 Jun 2009	09768694.3
PAT903785-US-PCT	US	25 Jun 2009	13/000460
PAT903785-US-PCTD	US	14 Dez 2016	15/378649
PAT903785-US-PSP	US	25 Jun 2008	61/075692
PAT903785-WO-PCT	WO	25 Jun 2009	PCT/CH09/000221
PAT903785-ZA-PCT	ZA	25 Jun 2009	2010/08595
PAT903786-AU-PCT	AU	20 Feb 2013	2013379444
PAT903786-CA-PCT	CA	20 Feb 2013	2896174
PAT903786-CN-PCT	CN	20 Feb 2013	201380069162.4
PAT903786-HK-FPR	HK	24 Jun 2016	16107384.1
PAT903786-JP-PCT	JP	20 Feb 2013	2015-557338
PAT903786-RU-PCT	RU	20 Feb 2013	2015139890
PAT903786-WO-PCT	WO	20 Feb 2013	PCT/EP2013/053329
PAT903787-US-NP	US	04 Feb 2014	12/823538
PAT903787-US-PSP	US	25 Jun 2009	61/220507
PAT903788-AU-PCT	AU	15 Feb 2013	2013378628
PAT903788-CA-PCT	CA	15 Feb 2013	2894918
PAT903788-CN-PCT	CN	15 Feb 2013	201380065987.9
PAT903788-HK-FPR	HK	25 Mai 2016	16105985.8
PAT903788-JP-PCT	JP	15 Feb 2013	2015-557333
PAT903788-RU-PCT	RU	15 Feb 2013	2015139095
PAT903788-WO-PCT	WO	15 Feb 2013	PCT/EP2013/053039
PAT903789-AU-PCT	AU	30 Jun 2009	2009270405
PAT903789-AU-PCTD	AU	20 Aug 2014	2014215955
PAT903789-AU-PCTD02	AU	03 Nov 2016	2016253633
PAT903789-BR-PCT	BR	30 Jun 2009	PI0915343-8

Novartis reference	Country	Filing Date	Filing Number
PAT903789-CA-PCT	CA	30 Jun 2009	2729185
PAT903789-CN-PCT	CN	30 Jun 2009	200980124781.2
PAT903789-CN-PCTD	CN	22 Okt 2015	201510689528.9
PAT903789-JP-PCT	JP	30 Jun 2009	2011-515053
PAT903789-JP-PCTD	JP	19 Mär 2014	2014-55758
PAT903789-JP-PCTD02	JP	20 Mai 2016	2016-101272
PAT903789-KR-PCT	KR	30 Jun 2009	2011-7001520
PAT903789-KR-PCTD	KR	18 Apr 2016	2016-7010129
PAT903789-MX-PCT	MX	30 Jun 2009	MX/a/2011/000006
PAT903789-MX-PCTD	MX	28 Sep 2012	MX/a/2012/011299
PAT903789-RU-PCT	RU	30 Jun 2009	2011103168
PAT903789-RU-PCTD	RU	10 Mär 2016	2016108598
PAT903789-US-PCT	US	30 Jun 2009	13/000499
PAT903789-US-PCTD	US	19 Dez 2013	14/134988
PAT903789-US-PCTD02	US	24 Mai 2016	15/163208
PAT903789-US-PSP	US	30 Jun 2008	61/076775
PAT903789-WO-PCT	WO	30 Jun 2009	PCT/CH09/000225
PAT903789-ZA-PCT	ZA	30 Jun 2009	2010/08596
PAT903790-AU-PCT	AU	22 Feb 2010	2010217120
PAT903790-AU-PCTD	AU	10 Apr 2013	2013203478
PAT903790-AU-PCTD02	AU	31 Aug 2016	2016222411
PAT903790-AU-PCTD03	AU	07 Jun 2018	2018204035
PAT903790-BR-PCT	BR	22 Feb 2010	PI1005398-0
PAT903790-CA-PCT	CA	22 Feb 2010	2744103
PAT903790-CH-EPT	CH	22 Feb 2010	10705086.6
PAT903790-CH-NP	CH	02 Jun 2009	CH-0832/09
PAT903790-CL-PCT	CL	22 Feb 2010	2011-1453
PAT903790-CN-PCT	CN	22 Feb 2010	201080003451.0
PAT903790-CN-PCTD	CN	21 Mai 2015	201510261116.5
PAT903790-DE-EPT	DE	22 Feb 2010	10705086.6
PAT903790-EG-PCT	EG	22 Feb 2010	677/2011
PAT903790-EP-EPT	EP	22 Feb 2010	10705086.6
PAT903790-EP-ETD	EP	05 Dez 2016	16202099.4
PAT903790-ES-EPT	ES	22 Feb 2010	10705086.6
PAT903790-FR-EPT	FR	22 Feb 2010	10705086.6
PAT903790-GB-EPT	GB	22 Feb 2010	10705086.6
PAT903790-HK-FPR	HK	20 Mai 2011	11105024.6
PAT903790-HK-FPR02	HK	19 Dez 2017	17113521.2
PAT903790-ID-PCT	ID	22 Feb 2010	W00201102623
PAT903790-IL-PCT	IL	22 Feb 2010	212738
PAT903790-IL-PCTD	IL	02 Jul 2013	226955
PAT903790-IL-PCTD02	IL	06 Jun 2013	226956
PAT903790-IL-PCTD03	IL	26 Mär 2015	237985
PAT903790-IL-PCTD04	IL	20 Nov 2018	263158
PAT903790-IN-PCT	IN	22 Feb 2010	1743KOLNP2011
PAT903790-IT-EPT	IT	22 Feb 2010	10705086.6
PAT903790-JP-PCT	JP	22 Feb 2010	2011-550396
PAT903790-JP-PCTD	JP	19 Mai 2015	2015-101581
PAT903790-JP-PCTD02	JP	28 Apr 2017	2017-90650
PAT903790-JP-PCTD03	JP	14 Sep 2018	2018-172287
PAT903790-KR-PCT	KR	22 Feb 2010	2011-7014643
PAT903790-KR-PCTD	KR	12 Feb 2016	2016-7003693
PAT903790-KR-PCTD02	KR	20 Dez 2016	2016-7035683

Novartis reference	Country	Filing Date	Filing Number
PAT903790-KR-PCTD03	KR	04 Jan 2018	2018-7000320
PAT903790-KR-PCTD04	KR	21 Feb 2019	2019-7005221
PAT903790-MX-PCT	MX	22 Feb 2010	MX/A/2011/007049
PAT903790-MX-PCTD	MX	16 Dez 2015	MX/A/2015/017453
PAT903790-MX-PCTD02	MX	08 Dez 2017	MX/A/2017/016012
PAT903790-PH-PCT	PH	22 Feb 2010	1-2011-500876
PAT903790-PH-PCTD	PH	05 Nov 2014	1-2014-502468
PAT903790-RU-PCT	RU	22 Feb 2010	2011124039
PAT903790-RU-PCTD	RU	02 Feb 2016	2016103262
PAT903790-RU-PCTD02	RU	09 Okt 2017	2017135831
PAT903790-SG-PCT	SG	22 Feb 2010	201103445-1
PAT903790-SG-PCTD	SG	13 Feb 2014	2014014864
PAT903790-SG-PCTD02	SG	10 Dez 2014	10201408247S
PAT903790-SG-PCTD03	SG	06 Okt 2017	10201708233V
PAT903790-US-CNT	US	14 Sep 2012	13/616267
PAT903790-US-CNT02	US	20 Nov 2015	14/947133
PAT903790-US-CNT03	US	17 Jan 2018	15/873022
PAT903790-US-DIV	US	22 Jun 2012	13/530241
PAT903790-US-DIV02	US	08 Mai 2014	14/273231
PAT903790-US-NP	US	23 Feb 2010	12/710579
PAT903790-US-PSP	US	24 Feb 2009	61/155105
PAT903790-WO-PCT	WO	22 Feb 2010	PCT/CH10/000044
PAT903790-ZA-PCT	ZA	22 Feb 2010	2011/03125
PAT903793-AL-EPT	AL	25 Jun 2009	09768693.5
PAT903793-AT-EPT	AT	25 Jun 2009	09768693.5
PAT903793-AU-PCT	AU	25 Jun 2009	2009264565
PAT903793-AU-PCTD	AU	08 Apr 2013	2013202998
PAT903793-AU-PCTD02	AU	01 Jul 2015	2015203705
PAT903793-AU-PCTD03	AU	27 Jun 2017	2017204337
PAT903793-BA-EPT	BA	25 Jun 2009	09768693.5
PAT903793-BE-EPT	BE	25 Jun 2009	09768693.5
PAT903793-BG-EPT	BG	25 Jun 2009	09768693.5
PAT903793-BR-PCT	BR	25 Jun 2009	PI0914251.7
PAT903793-CA-PCT	CA	25 Jun 2009	2727839
PAT903793-CA-PCTD	CA	10 Okt 2018	3020290
PAT903793-CH-EPT	CH	25 Jun 2009	09768693.5
PAT903793-CL-PCT	CL	25 Jun 2009	1544-2010
PAT903793-CN-PCT	CN	25 Jun 2009	200980124313.5
PAT903793-CN-PCTD	CN	28 Apr 2015	201510205513.0
PAT903793-CY-EPT	CY	25 Jun 2009	09768693.5
PAT903793-CZ-EPT	CZ	25 Jun 2009	09768693.5
PAT903793-DE-EPT	DE	25 Jun 2009	09768693.5
PAT903793-DK-EPT	DK	25 Jun 2009	09768693.5
PAT903793-EE-EPT	EE	25 Jun 2009	09768693.5
PAT903793-EG-PCT	EG	25 Jun 2009	2049/2010
PAT903793-EP-EPT	EP	25 Jun 2009	09768693.5
PAT903793-EP-ETD	EP	17 Jan 2017	17151756.8
PAT903793-ES-EPT	ES	25 Jun 2009	09768693.5
PAT903793-FI-EPT	FI	25 Jun 2009	09768693.5
PAT903793-FR-EPT	FR	25 Jun 2009	09768693.5
PAT903793-GB-EPT	GB	25 Jun 2009	09768693.5
PAT903793-GR-EPT	GR	25 Jun 2009	09768693.5
PAT903793-HK-FPD	HK	20 Dez 2017	17113558.8

Novartis reference	Country	Filing Date	Filing Number
PAT903793-HK-FPR	HK	19 Mai 2011	11104959.8
PAT903793-HR-EPT	HR	25 Jun 2009	09768693.5
PAT903793-HU-EPT	HU	25 Jun 2009	09768693.5
PAT903793-IE-EPT	IE	25 Jun 2009	09768693.5
PAT903793-IN-PCT	IN	25 Jun 2009	4909/KOLNP/2010
PAT903793-IS-EPT	IS	25 Jun 2009	09768693.5
PAT903793-IT-EPT	IT	25 Jun 2009	09768693.5
PAT903793-JP-PCT	JP	25 Jun 2009	2011-515049
PAT903793-JP-PCTD	JP	21 Apr 2014	2014-87194
PAT903793-JP-PCTD02	JP	27 Feb 2015	2015-037794
PAT903793-JP-PCTD03	JP	28 Dez 2016	2016-255720
PAT903793-JP-PCTD04	JP	05 Feb 2018	2018-018375
PAT903793-KR-PCT	KR	25 Jun 2009	2011-7001961
PAT903793-KR-PCTD	KR	11 Nov 2015	2015-7032314
PAT903793-KR-PCTD02	KR	27 Okt 2016	2016-7030125
PAT903793-KR-PCTD03	KR	12 Mai 2017	2017-7012884
PAT903793-KR-PCTD04	KR	04 Jan 2018	2018-7000324
PAT903793-KR-PCTD05	KR	28 Aug 2018	2018-7024733
PAT903793-LT-EPT	LT	25 Jun 2009	09768693.5
PAT903793-LU-EPT	LU	25 Jun 2009	09768693.5
PAT903793-LV-EPT	LV	25 Jun 2009	09768693.5
PAT903793-MA-EPT	MA	25 Jun 2009	09768693.5
PAT903793-MC-EPT	MC	25 Jun 2009	09768693.5
PAT903793-ME-EPT	ME	25 Jun 2009	09768693.5
PAT903793-MK-EPT	MK	25 Jun 2009	09768693.5
PAT903793-MT-EPT	MT	25 Jun 2009	09768693.5
PAT903793-MX-PCT	MX	25 Jun 2009	MX/a/2011/000011
PAT903793-MX-PCTD	MX	30 Apr 2013	MX/a/2013/004871
PAT903793-NL-EPT	NL	25 Jun 2009	09768693.5
PAT903793-NO-EPT	NO	25 Jun 2009	09768693.5
PAT903793-PH-PCT	PH	25 Jun 2009	1-2010-502919
PAT903793-PH-PCTD	PH	20 Jul 2015	2015-501593
PAT903793-PL-EPT	PL	25 Jun 2009	09768693.5
PAT903793-PT-EPT	PT	25 Jun 2009	09768693.5
PAT903793-RO-EPT	RO	25 Jun 2009	09768693.5
PAT903793-RS-EPT	RS	25 Jun 2009	09768693.5
PAT903793-RU-PCT	RU	25 Jun 2009	2011102583
PAT903793-RU-PCTD	RU	19 Jul 2013	2013133802
PAT903793-RU-PCTD02	RU	08 Aug 2014	2014132888
PAT903793-RU-PCTD03	RU	18 Mai 2016	2016119152
PAT903793-RU-PCTD04	RU	16 Feb 2018	2018105866
PAT903793-SE-EPT	SE	25 Jun 2009	09768693.5
PAT903793-SI-EPT	SI	25 Jun 2009	09768693.5
PAT903793-SK-EPT	SK	25 Jun 2009	09768693.5
PAT903793-SM-EPT	SM	25 Jun 2009	09768693.5
PAT903793-TR-EPT	TR	25 Jun 2009	09768693.5
PAT903793-US-PCT	US	25 Jun 2009	13/000423
PAT903793-US-PCTD	US	07 Dez 2012	13/708575
PAT903793-US-PCTD02	US	16 Jun 2015	14/741430
PAT903793-US-PCTD03	US	16 Nov 2017	15/814784
PAT903793-US-PSP	US	25 Jun 2008	61/133212
PAT903793-WO-PCT	WO	25 Jun 2009	PCT/CH09/000220
PAT903793-ZA-PCT	ZA	25 Jun 2009	2010/08594

Novartis reference	Country	Filing Date	Filing Number
PAT903797-AT-EPT	AT	25 Jun 2009	09768692.7
PAT903797-AU-PCT	AU	25 Jun 2009	2009264564
PAT903797-AU-PCTD	AU	08 Apr 2013	2013202997
PAT903797-AU-PCTD02	AU	09 Apr 2015	2015201794
PAT903797-AU-PCTD03	AU	16 Dez 2016	2016273957
PAT903797-AU-PCTD04	AU	24 Dez 2018	2018285441
PAT903797-BE-EPT	BE	25 Jun 2009	09768692.7
PAT903797-BG-EPT	BG	25 Jun 2009	09768692.7
PAT903797-BR-PCT	BR	25 Jun 2009	PI0914319-0
PAT903797-CA-PCT	CA	25 Jun 2009	2727992
PAT903797-CH-EPT	CH	25 Jun 2009	09768692.7
PAT903797-CL-PCT	CL	25 Jun 2009	2010-1543
PAT903797-CN-PCT	CN	25 Jun 2009	200980123825.X
PAT903797-CN-PCTD	CN	27 Jun 2017	201710511379.6
PAT903797-CZ-EPT	CZ	25 Jun 2009	09768692.7
PAT903797-DE-EPT	DE	25 Jun 2009	09768692.7
PAT903797-DK-EPT	DK	25 Jun 2009	09768692.7
PAT903797-EG-PCT	EG	25 Jun 2009	2048/2010
PAT903797-EP-EPT	EP	25 Jun 2009	09768692.7
PAT903797-EP-ETD	EP	12 Jun 2018	18177227.8
PAT903797-ES-EPT	ES	25 Jun 2009	09768692.7
PAT903797-FI-EPT	FI	25 Jun 2009	09768692.7
PAT903797-FR-EPT	FR	25 Jun 2009	09768692.7
PAT903797-GB-EPT	GB	25 Jun 2009	09768692.7
PAT903797-GR-EPT	GR	25 Jun 2009	09768692.7
PAT903797-HK-FPR	HK	18 Mai 2011	11104927.7
PAT903797-HU-EPT	HU	25 Jun 2009	09768692.7
PAT903797-IE-EPT	IE	25 Jun 2009	09768692.7
PAT903797-IN-PCT	IN	25 Jun 2009	4924/KOLNP/2010
PAT903797-IS-EPT	IS	25 Jun 2009	09768692.7
PAT903797-IT-EPT	IT	25 Jun 2009	09768692.7
PAT903797-JP-PCT	JP	25 Jun 2009	2011-515048
PAT903797-JP-PCTD	JP	23 Jan 2015	2015-10886
PAT903797-JP-PCTD02	JP	16 Dez 2016	2016-244030
PAT903797-KR-PCT	KR	25 Jun 2009	2011-7001793
PAT903797-KR-PCTD	KR	25 Okt 2016	2016-7029809
PAT903797-KR-PCTD02	KR	23 Aug 2018	2018-7024302
PAT903797-MX-PCT	MX	25 Jun 2009	2011/000075
PAT903797-MX-PCTD	MX	27 Mär 2014	MX/a/2014/003709
PAT903797-MX-PCTD02	MX	08 Jul 2016	MX/A/2016/008990
PAT903797-NL-EPT	NL	25 Jun 2009	09768692.7
PAT903797-NO-EPT	NO	25 Jun 2009	09768692.7
PAT903797-PH-PCT	PH	25 Jun 2009	1-2010-502822
PAT903797-PH-PCTD	PH	01 Sep 2014	1-2014-501962
PAT903797-PL-EPT	PL	25 Jun 2009	09768692.7
PAT903797-PT-EPT	PT	25 Jun 2009	09768692.7
PAT903797-RO-EPT	RO	25 Jun 2009	09768692.7
PAT903797-RU-PCT	RU	25 Jun 2009	2011102579
PAT903797-RU-PCTD	RU	10 Sep 2015	2015138696
PAT903797-RU-PCTD02	RU	11 Apr 2018	2018113177
PAT903797-RU-PCTD03	RU	27 Dez 2018	2018146937
PAT903797-SE-EPT	SE	25 Jun 2009	09768692.7
PAT903797-SI-EPT	SI	25 Jun 2009	09768692.7

Novartis reference	Country	Filing Date	Filing Number
PAT903797-SK-EPT	SK	25 Jun 2009	09768692.7
PAT903797-TR-EPT	TR	25 Jun 2009	09768692.7
PAT903797-US-PCT	US	25 Jun 2009	13/000345
PAT903797-US-PCTD	US	19 Dez 2013	14/134779
PAT903797-US-PCTD02	US	18 Mai 2016	15/157641
PAT903797-US-PCTD03	US	12 Sep 2018	16/128691
PAT903797-US-PSP	US	25 Jun 2008	61/075640
PAT903797-US-PSP02	US	26 Jun 2008	61/075956
PAT903797-WO-PCT	WO	25 Jun 2009	PCT/CH09/000219
PAT903797-ZA-PCT	ZA	25 Jun 2009	2010/08593
PAT903797-ZA-PCTD	ZA	21 Nov 2013	2013/08787
PAT903797-ZA-PCTD02	ZA	20 Mai 2016	2016/03485
PAT903798-AT-EPT	AT	10 Jul 2007	07763939.1
PAT903798-AU-PCT	AU	10 Jul 2007	2007272224
PAT903798-AU-PCTD	AU	10 Apr 2013	2013203533
PAT903798-AU-PCTD02	AU	22 Jan 2016	2016200367
PAT903798-AU-PCTD03	AU	26 Sep 2017	2017235901
PAT903798-BE-EPT	BE	10 Jul 2007	07763939.1
PAT903798-BG-EPT	BG	10 Jul 2007	07763939.1
PAT903798-CA-PCT	CA	10 Jul 2007	2658241
PAT903798-CH-EPT	CH	10 Jul 2007	07763939.1
PAT903798-CN-PCT	CN	10 Jul 2007	200780031471.7
PAT903798-CN-PCTD	CN	03 Mai 2013	201310159387.0
PAT903798-CZ-EPT	CZ	10 Jul 2007	07763939.1
PAT903798-DE-EPT	DE	10 Jul 2007	07763939.1
PAT903798-DK-EPT	DK	10 Jul 2007	07763939.1
PAT903798-EP-EPT	EP	10 Jul 2007	07763939.1
PAT903798-EP-ETD	EP	22 Jun 2016	16175728.1
PAT903798-ES-EPT	ES	10 Jul 2007	07763939.1
PAT903798-FI-EPT	FI	10 Jul 2007	07763939.1
PAT903798-FR-EPT	FR	10 Jul 2007	07763939.1
PAT903798-GB-EPT	GB	10 Jul 2007	07763939.1
PAT903798-GR-EPT	GR	10 Jul 2007	07763939.1
PAT903798-HK-FPR	HK	15 Mai 2009	09104447.2
PAT903798-HK-FPR02	HK	20 Feb 2017	17101824.1
PAT903798-HR-EPT	HR	10 Jul 2007	07763939.1
PAT903798-HU-EPT	HU	10 Jul 2007	07763939.1
PAT903798-IE-EPT	IE	10 Jul 2007	07763939.1
PAT903798-IN-PCT	IN	10 Jul 2007	532/DELNP/2009
PAT903798-IT-EPT	IT	10 Jul 2007	07763939.1
PAT903798-JP-PCT	JP	10 Jul 2007	2009-518698
PAT903798-JP-PCTD	JP	16 Jun 2014	2014-123202
PAT903798-JP-PCTD02	JP	16 Jun 2014	2014-123201
PAT903798-JP-PCTD03	JP	21 Dez 2015	2015-248371
PAT903798-JP-PCTD04	JP	01 Sep 2017	2017-168662
PAT903798-JP-PCTD05	JP	04 Feb 2019	2019-17744
PAT903798-LT-EPT	LT	10 Jul 2007	07763939.1
PAT903798-LU-EPT	LU	10 Jul 2007	07763939.1
PAT903798-LV-EPT	LV	10 Jul 2007	07763939.1
PAT903798-NL-EPT	NL	10 Jul 2007	07763939.1
PAT903798-NO-EPT	NO	10 Jul 2007	07763939.1
PAT903798-NZ-PCT	NZ	10 Jul 2007	574308
PAT903798-NZ-PCTD	NZ	03 Feb 2012	598025

Novartis reference	Country	Filing Date	Filing Number
PAT903798-NZ-PCTD02	NZ	18 Apr 2013	609597
PAT903798-NZ-PCTD03	NZ	28 Jan 2016	715153
PAT903798-NZ-PCTD04	NZ	24 Jul 2017	733997
PAT903798-PL-EPT	PL	10 Jul 2007	07763939.1
PAT903798-PT-EPT	PT	10 Jul 2007	07763939.1
PAT903798-RO-EPT	RO	10 Jul 2007	07763939.1
PAT903798-RU-PCT	RU	10 Jul 2007	2009104318
PAT903798-RU-PCTD	RU	10 Jul 2007	2011126239
PAT903798-RU-PCTD02	RU	21 Jul 2015	2015130221
PAT903798-SE-EPT	SE	10 Jul 2007	07763939.1
PAT903798-SI-EPT	SI	10 Jul 2007	07763939.1
PAT903798-SK-EPT	SK	10 Jul 2007	07763939.1
PAT903798-TR-EPT	TR	10 Jul 2007	07763939.1
PAT903798-US-PCT	US	10 Jul 2007	12/307875
PAT903798-US-PCTD	US	30 Apr 2014	14/266444
PAT903798-US-PSP	US	06 Feb 2007	60/899907
PAT903798-US-PSP02	US	10 Jul 2006	60/819378
PAT903798-WO-PCT	WO	10 Jul 2007	PCT/CH07/000334
PAT903799-AU-PCT	AU	10 Jul 2009	2009267729
PAT903799-JP-PCT	JP	10 Jul 2009	2011-516941
PAT903799-JP-PCTD	JP	12 Feb 2014	2014-24529
PAT903799-MX-PCT	MX	10 Jul 2009	MX/a/2011/000009
PAT903799-RU-PCT	RU	10 Jul 2009	2011104816
PAT903799-US-PCT	US	10 Jul 2009	13/000533
PAT903799-US-PCTD	US	26 Feb 2014	14/190788
PAT903799-US-PSP	US	10 Jul 2008	61/079586
PAT903799-WO-PCT	WO	10 Jul 2009	PCT/CH09/000248
PAT903799-ZA-PCT	ZA	10 Jul 2009	2010/08597
PAT903921-AL-EPT	AL	24 Okt 2011	11776322.7
PAT903921-AR-NP	AR	20 Okt 2011	P110103885
PAT903921-AT-EPT	AT	24 Okt 2011	11776322.7
PAT903921-AU-PCT	AU	24 Okt 2011	2011318179
PAT903921-AU-PCTD	AU	09 Apr 2013	2013203189
PAT903921-AU-PCTD02	AU	05 Feb 2015	2015200534
PAT903921-AU-PCTD03	AU	21 Dez 2016	2016277637
PAT903921-AU-PCTD04	AU	15 Okt 2018	2018247355
PAT903921-BE-EPT	BE	24 Okt 2011	11776322.7
PAT903921-BG-EPT	BG	24 Okt 2011	11776322.7
PAT903921-BR-PCT	BR	24 Okt 2011	112013010949-1
PAT903921-CA-PCT	CA	24 Okt 2011	2814766
PAT903921-CH-EPT	CH	24 Okt 2011	11776322.7
PAT903921-CL-PCT	CL	24 Okt 2011	2013-1089
PAT903921-CL-PCTD	CL	15 Sep 2015	2015-2735
PAT903921-CN-PCT	CN	24 Okt 2011	201180050388.0
PAT903921-CN-PCTD	CN	23 Mär 2018	201810249347.8
PAT903921-CO-PCT	CO	24 Okt 2011	13102367
PAT903921-CO-PCTD	CO	31 Jul 2015	15178564
PAT903921-CO-PCTD02	CO	14 Sep 2015	15216687
PAT903921-CY-EPT	CY	24 Okt 2011	11776322.7
PAT903921-CZ-EPT	CZ	24 Okt 2011	11776322.7
PAT903921-DE-EPT	DE	24 Okt 2011	11776322.7
PAT903921-DK-EPT	DK	24 Okt 2011	11776322.7
PAT903921-EE-EPT	EE	24 Okt 2011	11776322.7

Novartis reference	Country	Filing Date	Filing Number
PAT903921-EG-PCT	EG	24 Okt 2011	PCT/419/2013
PAT903921-EP-EPT	EP	24 Okt 2011	11776322.7
PAT903921-EP-ETD	EP	16 Nov 2017	17202052.1
PAT903921-ES-EPT	ES	24 Okt 2011	11776322.7
PAT903921-FI-EPT	FI	24 Okt 2011	11776322.7
PAT903921-FR-EPT	FR	24 Okt 2011	11776322.7
PAT903921-GB-EPT	GB	24 Okt 2011	11776322.7
PAT903921-GC-NP	GC	22 Okt 2011	2011-19573
PAT903921-GR-EPT	GR	24 Okt 2011	11776322.7
PAT903921-HK-FPR	HK	21 Feb 2014	14101686.1
PAT903921-HK-FPR02	HK	05 Dez 2018	18115570.6
PAT903921-HR-EPT	HR	24 Okt 2011	11776322.7
PAT903921-HU-EPT	HU	24 Okt 2011	11776322.7
PAT903921-IE-EPT	IE	24 Okt 2011	11776322.7
PAT903921-IN-PCT	IN	24 Okt 2011	1275/KOLNP/2013
PAT903921-IS-EPT	IS	24 Okt 2011	11776322.7
PAT903921-IT-EPT	IT	24 Okt 2011	11776322.7
PAT903921-JP-PCT	JP	24 Okt 2011	2013-534142
PAT903921-JP-PCTD	JP	31 Jul 2015	2015-151924
PAT903921-JP-PCTD02	JP	24 Jul 2017	2017-142892
PAT903921-JP-PCTD03	JP	05 Dez 2018	2018-227992
PAT903921-KR-PCT	KR	24 Okt 2011	2013-7012905
PAT903921-KR-PCTD	KR	28 Jun 2016	2016-7017314
PAT903921-KR-PCTD02	KR	16 Feb 2017	2017-7004318
PAT903921-KR-PCTD03	KR	07 Feb 2019	2019-7003613
PAT903921-LT-EPT	LT	24 Okt 2011	11776322.7
PAT903921-LU-EPT	LU	24 Okt 2011	11776322.7
PAT903921-LV-EPT	LV	24 Okt 2011	11776322.7
PAT903921-MC-EPT	MC	24 Okt 2011	11776322.7
PAT903921-MK-EPT	MK	24 Okt 2011	11776322.7
PAT903921-MT-EPT	MT	24 Okt 2011	11776322.7
PAT903921-MX-PCT	MX	24 Okt 2011	MX/A/2013/004295
PAT903921-MX-PCTD	MX	23 Jul 2014	MX/a/2014/008904
PAT903921-MX-PCTD02	MX	09 Jun 2017	MX/a/2017/007557
PAT903921-NL-EPT	NL	24 Okt 2011	11776322.7
PAT903921-NO-EPT	NO	24 Okt 2011	11776322.7
PAT903921-PH-PCT	PH	24 Okt 2011	1-2013-500675
PAT903921-PL-EPT	PL	24 Okt 2011	11776322.7
PAT903921-PT-EPT	PT	24 Okt 2011	11776322.7
PAT903921-RO-EPT	RO	24 Okt 2011	11776322.7
PAT903921-RS-EPT	RS	24 Okt 2011	11776322.7
PAT903921-RU-PCT	RU	24 Okt 2011	2013123266
PAT903921-RU-PCTD	RU	22 Mai 2015	2015119440
PAT903921-SE-EPT	SE	24 Okt 2011	11776322.7
PAT903921-SI-EPT	SI	24 Okt 2011	11776322.7
PAT903921-SK-EPT	SK	24 Okt 2011	11776322.7
PAT903921-TH-PCT	TH	24 Okt 2011	PCT/CH2011/000256
PAT903921-TR-EPT	TR	24 Okt 2011	11776322.7
PAT903921-TW-DIV	TW	29 Okt 2015	104135587
PAT903921-TW-DIV02	TW	08 Okt 2018	107135410
PAT903921-TW-NP	TW	21 Okt 2011	100138294
PAT903921-UA-PCT	UA	24 Okt 2011	A201304030
PAT903921-UA-PCTD	UA	11 Dez 2015	a201512291

Novartis reference	Country	Filing Date	Filing Number
PAT903921-US-DIV	US	28 Aug 2013	14/011831
PAT903921-US-DIV02	US	18 Feb 2016	15/047541
PAT903921-US-NP	US	21 Okt 2011	13/278500
PAT903921-US-PSP	US	22 Okt 2010	61/405798
PAT903921-US-PSP02	US	11 Mai 2011	61/484749
PAT903921-UY-NP	UY	20 Okt 2011	33679
PAT903921-WO-PCT	WO	24 Okt 2011	PCT/CH2011/000256
PAT903921-ZA-PCT	ZA	24 Okt 2011	2013/02537
PAT903970-US-PSP	US	15 Aug 2011	61/523604
PAT905045-AR-NP	AR	19 Okt 2012	P120103914
PAT905045-AU-PCT	AU	19 Okt 2012	2012325232
PAT905045-BR-PCT	BR	19 Okt 2012	112014009030-0
PAT905045-CA-PCT	CA	19 Okt 2012	2850572
PAT905045-CH-EPT	CH	19 Okt 2012	12780659.4
PAT905045-CN-PCT	CN	19 Okt 2012	201280051247.5
PAT905045-CN-PCTD	CN	25 Okt 2018	201811254222.0
PAT905045-DE-EPT	DE	19 Okt 2012	12780659.4
PAT905045-EP-EPT	EP	19 Okt 2012	12780659.4
PAT905045-EP-ETD	EP	12 Jun 2018	18177236.9
PAT905045-ES-EPT	ES	19 Okt 2012	12780659.4
PAT905045-FR-EPT	FR	19 Okt 2012	12780659.4
PAT905045-GB-EPT	GB	19 Okt 2012	12780659.4
PAT905045-GC-NP	GC	17 Okt 2012	2012-22585
PAT905045-IT-EPT	IT	19 Okt 2012	12780659.4
PAT905045-JP-PCT	JP	19 Okt 2012	2014-536147
PAT905045-JP-PCTD	JP	21 Apr 2017	2017-84447
PAT905045-JP-PCTD02	JP	29 Mär 2019	2019-067016
PAT905045-KR-PCT	KR	19 Okt 2012	2014-7009866
PAT905045-MX-PCT	MX	19 Okt 2012	MX/A/2014/004521
PAT905045-RU-PCT	RU	19 Okt 2012	2014120154
PAT905045-TW-NP	TW	19 Okt 2012	101138704
PAT905045-US-CNT	US	27 Feb 2019	16/286816
PAT905045-US-NP	US	19 Okt 2012	13/655743
PAT905045-US-PSP	US	20 Okt 2011	61/549482
PAT905045-UY-NP	UY	19 Okt 2012	34.404
PAT905045-WO-PCT	WO	19 Okt 2012	PCT/EP2012/004404
PAT905076-DE-EPT	DE	31 Jan 2013	13705737.8
PAT905076-EP-EPT	EP	31 Jan 2013	13705737.8
PAT905076-ES-EPT	ES	31 Jan 2013	13705737.8
PAT905076-FR-EPT	FR	31 Jan 2013	13705737.8
PAT905076-GB-EPT	GB	31 Jan 2013	13705737.8
PAT905076-IT-EPT	IT	31 Jan 2013	13705737.8
PAT905076-JP-PCT	JP	31 Jan 2013	2014-555204
PAT905076-JP-PCTD	JP	03 Jul 2017	2017-130349
PAT905076-JP-PCTD02	JP	28 Feb 2019	2019-036141
PAT905076-US-DIV	US	18 Aug 2014	14/462065
PAT905076-US-DIV02	US	24 Aug 2016	15/245767
PAT905076-US-DIV03	US	04 Sep 2018	16/120523
PAT905076-US-NP	US	01 Feb 2013	13/756932
PAT905076-WO-PCT	WO	31 Jan 2013	PCT/EP2013/051907



COMMERCIAL REGISTER OF CANTON ZURICH

Identification number	Legal status	Entry	Cancelled	Carried CH-020.3.021.104-7 from: CH-020.3.021.104-7/a on:	1
CHE-104.809.432	Limited liability company	04.09.1998			



All datas

In	Ca	Business name	Ref	Legal seat
1	2	ESBATEch AG	1	Schlieren
1	2	(ESBATEch SA) (ESBATEch Inc)		
2	6	ESBATEch, an Alcon Biomedical Research Unit GmbH		
2	6	(ESBATEch, an Alcon Biomedical Research Unit Sàrl) (ESBATEch, an Alcon Biomedical Research Unit LLC)		
6	9	ESBATEch, a Novartis Company GmbH		
6	9	(ESBATEch, a Novartis Company Sàrl) (ESBATEch, a Novartis Company LLC)		
9		ESBATEch, a Novartis company GmbH		
9		(ESBATEch, a Novartis company Sàrl) (ESBATEch, a Novartis company LLC)		

Ref	Capital	In	Mo	Ca	Shares	Partner (see personalities)	In	Ca	Company address
1	43'964'424.00	2			1x13'964'424.00	Alcon Research Ltd., in Fort Worth (TX)	1	11	Wagistrasse 24
2	13'964'424.00						11		8952 Schlieren
									Wagistrasse 12
									8952 Schlieren

In	Ca	Purpose	In	Ca	Postal address
1	2	Identifizierung und Optimierung von Substanzen, welche anschliessend in der Medikamentenentwicklung eingesetzt werden können; kann sich an anderen Unternehmen beteiligen sowie Grundeigentum erwerben, belasten, veräussern und verwalten.	1		
2		Die Gesellschaft bezweckt die Identifizierung und Optimierung von Substanzen, welche anschliessend in der Medikamentenentwicklung eingesetzt werden können. Die Gesellschaft kann Zweigniederlassungen und Tochtergesellschaften im In- und Ausland errichten und jede Art von Unternehmen erwerben, halten, veräussern oder finanzieren. Die Gesellschaft kann Grundstücke erwerben, halten und veräussern. Sie kann alle kommerziellen Tätigkeiten ausüben, welche direkt oder indirekt mit dem Zweck der Gesellschaft im Zusammenhang stehen, und alle Massnahmen ergreifen, die den Gesellschaftszweck angemessen zu fördern scheinen oder mit diesem im Zusammenhang stehen.			

In	Ca	Remarks	Ref	Date of the acts
1		Kapitalerhöhung in der Höhe von CHF 34'500.-- aus bedingtem Aktienkapital.	1	01.09.1998
1		Ordentliche Erhöhung des Aktienkapitals.	1	24.05.2000
1		Kapitalerhöhung aus genehmigten Aktienkapital.	1	27.04.2001
1		Kapitalerhöhung aus bedingtem Aktienkapital.	1	25.10.2001
1	2	Die Gesellschaft hat mit Beschluss vom 04.05.2002 eine bedingte Kapitalerhöhung gemäss näherer Umschreibung in den Statuten beschlossen.	1	08.05.2002
1	2	Die Mitteilungen an die Namenaktionäre erfolgen im Falle von Art.10 an ihre letzte im Aktienbuch eingetragene Adresse durch Brief oder per Telefax. In allen anderen Fällen können die Mitteilungen durch Veröffentlichung im Publikationsorgan erfolgen.	1	13.11.2002
1	2	Die Übertragbarkeit der Namenaktien ist nach Massgabe der Statuten beschränkt.	1	19.11.2002
1	2	Die Vorzugsaktien gewähren Vorrechte bezüglich Bezug neuer Aktien und Liquidationserlös gemäss Statuten.	1	23.02.2004
1	2	Die Vorzugsaktien gewähren Vorrechte bezüglich Bezug neuer Aktien und Liquidationserlös gemäss Statuten.	1	19.04.2004
1		Bei der Kapitalherabsetzung vom 30.06.2006/02.08.2006 wird der Nennwert der 460'320 Namenaktien zu CHF 10.-- (Vorzugsaktien) auf CHF 4.-- und 11'500 Namenaktien zu CHF 10.-- auf CHF 4.-- herabgesetzt. Gleichzeitig werden 725'806 voll liberierte Namenaktien zu CHF 4.-- (Vorzugsaktien) ausgegeben.	1	21.01.2005
2		Mitteilungen an die Gesellschafter erfolgen schriftlich, per Brief, E-Mail oder Telefax.	1	11.02.2005
2		Vom Gesetz abweichende Abtretungsmodalitäten der Stammanteile gemäss Statuten.	1	30.06.2006
			1	02.08.2006
			1	26.04.2007
			1	09.10.2007
			1	25.06.2008
			1	21.07.2008
			1	18.12.2008
			1	07.04.2009



COMMERCIAL REGISTER OF CANTON ZURICH

CHE-104.809.432	ESBATEch, a Novartis company GmbH	Schlieren	2
-----------------	-----------------------------------	-----------	---

All datas

In	Ca	Remarks	Ref	Date of the acts
			1	04.05.2009
			2	08.10.2009
			6	20.01.2012
			9	15.01.2013

In	Ca	Qualified facts	Ref	Official publication
1		Vermögensübertragung: Die ESBATEch AG überträgt gemäss Vertrag vom 19.09.2006 Aktiven von CHF 231'259.-- und Passiven (Fremdkapital) von CHF 0.-- auf die Oncalls AG, in Schlieren (CH-020.3.030.003-2). Gegenleistung: CHF 231'259.--.	1	SHAB
2		Umwandlung: Die Gesellschaft wird gemäss Umwandlungsplan vom 06.10.2009 und Bilanz per 30.04.2009 mit Aktiven von CHF 27'874'806.00 und Passiven (Fremdkapital) von CHF 3'335'527.00 in eine Gesellschaft mit beschränkter Haftung umgewandelt. Die Alleinaktionärin erhält 1 Stammanteil zu CHF 13'964'424.00.		

In	Ca	Additional payments and statutory duty of accessory payments	In	Ca	Branch offices

Vis	Ref	No journal	Date	SOGC	Date SOGC	Page / Id	Vis	Ref	No journal	Date	SOGC	Date SOGC	Page / Id
ZH	1	37316	24.09.2009	189	30.09.2009	28 / 5270050	ZH	7	B 5754	13.02.2012	B 33	16.02.2012	6552850
ZH	2	39998	13.10.2009	202	19.10.2009	24 / 5298900	ZH	8	39904	21.11.2012	230	26.11.2012	6946438
ZH	3	45464	20.11.2009	230	26.11.2009	22 / 5361862	ZH	9	1990	21.01.2013	16	24.01.2013	7031432
ZH	4	7864	24.02.2011	42	01.03.2011	6056394	ZH	10	33097	17.10.2013	204	22.10.2013	1138539
ZH	5	22767	23.06.2011	123	28.06.2011	6225112	ZH	11	1752	15.01.2014	12	20.01.2014	1293821
ZH	6	3278	24.01.2012	19	27.01.2012	6522934							

In	Mo	Ca	Personal Data	Function	Signature
1		2m	Roper, Jeffrey L., amerikanischer Staatsangehöriger, in Kennedale (TX, US)	member of the board of directors	single signature
1		2m	Escher, Dominik, von Zürich, in Hausen am Albis	director	joint signature at two
1		2	Ernst & Young AG, in Aarau	auditor	
1		8	Schuh, Andreas, österreichischer Staatsangehöriger, in Genève		joint signature at two
2		4m	Escher, Dominik, von Zürich, in Zug	director	joint signature at two
2		9	Roper, Jeffrey L., amerikanischer Staatsangehöriger, in Kennedale (TX, US)	manager	single signature
2			Alcon Research Ltd., in Fort Worth (TX, US)	partner	
2		5	Ernst & Young AG (CH-270.3.012.140-6), in Basel	auditor	
3		9	Markabi, Dr. Sabri, französischer Staatsangehöriger, in Benbrook (TX, US)	president of the management	single signature
3		8	Beck, Jeanne, amerikanische Staatsangehörige, in Villars-sur-Glâne		single signature
4		9m	Escher, Dominik, von Zürich, in Hünenberg	director	joint signature at two
4			Schmidt, Annette, deutsche Staatsangehörige, in Zürich		joint signature at two
4			Steiner, Peter, von Schänis, in Wädenswil		joint signature at two
4			von Schulthess Rechberg, Konstantin, von Zürich, in Zollikon		joint signature at two
5			PricewaterhouseCoopers AG (CH-020.9.001.009-7), in Winterthur	auditor	
6		10	Gaudreault, Jacques, kanadischer Staatsangehöriger, in Basel		joint signature at two
6		7m	Weissgerber, Georges Charles, französischer Staatsangehöriger, in Zürich		joint signature at two
7			Weissgerber, Georges Charles, französischer Staatsangehöriger, in Marckolsheim (FR)		joint signature at two
8			Ryter Ciampi, Lea, von Kandergrund, in Olten		joint signature at two
8			Pflüter, Simone Doris, von Pratteln, in Pratteln		joint signature at two
9			Escher, Dominik, von Zürich, in Hünenberg	manager	joint signature at two
9			Klee, Christian, von Diepfingen und Rüeggisberg, in Winchester (MA/US)	president of the management	joint signature at two

Zürich, 20.02.2014 21:43

Continuation on the following page



COMMERCIAL REGISTER OF CANTON ZURICH

CHE-104.809.432	ESBATEch, a Novartis company GmbH	Schliffleren	3
-----------------	-----------------------------------	--------------	---

All datas

In	Mo	Ca	Personal Data	Function	Signature
9			Brenneisen, Pascal Andreas, von Basel, in Riehen	manager	joint signature at two
9			Dryja, Thaddeus P., amerikanischer Staatsangehöriger, in Milton (MA/US)	manager	joint signature at two
9			Scheibler, Lukas, von Oftringen, in Fort Worth (TX/US)	manager	joint signature at two
10			Maurer, Patrik, deutscher Staatsangehöriger, in Winterthur		joint signature at two

Zürich, 20.02.2014 21:43

The information above is given with not commitment and is in no way legally binding. Only the company record (extract) issued and certified by the commercial Registry Office of Zurich and the text published in the Swiss Commercial Gazette are binding.

The information above is given with no commitment and is in no way legally binding.



Handelsregisteramt des Kantons Basel-Stadt

Firmennummer	Rechtsnatur	Eintragung	Löschung	Übertrag CH-020.3.021.104-7 von: auf:	1
CHE-104.809.432	Gesellschaft mit beschränkter Haftung	23.05.2017			



Alle Eintragungen

Ei	Lö	Firma	Ref	Sitz
0		ESBATEch, a Novartis company GmbH	0	bisher:Schlieren
0		(ESBATEch, a Novartis company Sàrl) (ESBATEch, a Novartis company LLC)	1	Basel

Ref	Stammkap.(CHF)	Ei	Ae	Lö	Stammanteile	Gesellschafter (siehe Personalangaben)	Ei	Lö	Domiziladresse
0	13'964'424.00	0			1 x 13'964'424.00	Alcon Research Ltd.	0	1	Wagistrasse 12 8952 Schlieren c/o Novartis Pharma AG Lichtstrasse 35 4056 Basel

Ei	Lö	Zweck	Ei	Lö	weitere Adressen
0		Die Gesellschaft bezweckt die Identifizierung und Optimierung von Substanzen, welche anschliessend in der Medikamentenentwicklung eingesetzt werden können. Die Gesellschaft kann Zweigniederlassungen und Tochtergesellschaften im In- und Ausland errichten und jede Art von Unternehmen erwerben, halten, veräussern oder finanzieren. Die Gesellschaft kann Grundstücke erwerben, halten und veräussern. Sie kann alle kommerziellen Tätigkeiten ausüben, welche direkt oder indirekt mit dem Zweck der Gesellschaft im Zusammenhang stehen, und alle Massnahmen ergreifen, die den Gesellschaftszweck angemessen zu fördern scheinen oder mit diesem im Zusammenhang stehen.			

Ei	Lö	Bemerkungen	Ref	Statutendatum
0		Vom Gesetz abweichende Abtretungsmodalitäten der Stammanteile gemäss Statuten.	0	01.09.1998
0		Mitteilungen an die Gesellschafter erfolgen schriftlich, per Brief, E-Mail oder Telefax.	0	24.05.2000
0		Bei der Kapitalherabsetzung vom 30.06.2006/02.08.2006 wird der Nennwert der 460'320 Namenaktien zu CHF 10.-- (Vorzugsaktien) auf CHF 4.-- und 11'500 Namenaktien zu CHF 10.-- auf CHF 4.-- herabgesetzt. Gleichzeitig werden 725'806 voll liberierte Namenaktien zu CHF 4.-- (Vorzugsaktien) ausgegeben.	0	27.04.2001
			0	25.10.2001
			0	08.05.2002
0		Kapitalerhöhung aus bedingtem Aktienkapital.	0	13.11.2002
0		Kapitalerhöhung in der Höhe von CHF 34'500.-- aus bedingtem Aktienkapital.	0	19.11.2002
0		Ordentliche Erhöhung des Aktienkapitals.	0	23.02.2004
0		Kapitalerhöhung aus genehmigten Aktienkapital.	0	19.04.2004
			0	21.01.2005
			0	11.02.2005
			0	30.06.2006
			0	02.08.2006
			0	26.04.2007
			0	09.10.2007
			0	25.06.2008
			0	21.07.2008
			0	18.12.2008
			0	07.04.2009
			0	04.05.2009
			0	08.10.2009
			0	20.01.2012
			0	15.01.2013
			1	02.05.2017



Handelsregisteramt des Kantons Basel-Stadt

CHE-104.809.432	ESBATEch, a Novartis company GmbH	Basel	2
-----------------	-----------------------------------	-------	---


Alle Eintragungen

Ei	Lö	Besondere Tatbestände	Ref.	Publikationsorgan
0		Vermögensübertragung: Die ESBATEch AG überträgt gemäss Vertrag vom 19.09.2006 Aktiven von CHF 231'259.-- und Passiven (Fremdkapital) von CHF 0.-- auf die Oncalis AG, in Schlieren (CH-020.3.030.003-2). Gegenleistung: CHF 231'259.--.	0	SHAB
0		Umwandlung: Die Gesellschaft wird gemäss Umwandlungsplan vom 06.10.2009 und Bilanz per 30.04.2009 mit Aktiven von CHF 27'874'606.00 und Passiven (Fremdkapital) von CHF 3'335'527.00 in eine Gesellschaft mit beschränkter Haftung umgewandelt. Die Alleinaktionärin erhält 1 Stammanteil zu CHF 13'964'424.00.		

Ze	Ref	TR-Nr	TR-Datum	SHAB	SHAB-Dat.	Seite / Id	Ze	Ref	TR-Nr	TR-Datum	SHAB	SHAB-Dat.	Seite / Id
BS	0		(Sitzverlegung)		(Sitzverlegung)								
BS	1	2898	23.05.2017	102	29.05.2017	3547095							

Ei	Ae	Lö	Personalangaben	Funktion	Zeichnungsart
0			Alcon Research Ltd., in Fort Worth (US)	Gesellschafterin	
0	1		Brubaker, Dr. Michael Jay, amerikanischer Staatsangehöriger, in Fort Worth (US)	Geschäftsführer	Kollektivunterschrift zu zweien
0	1		Dryja, Thaddeus P., amerikanischer Staatsangehöriger, in Milton (US)	Geschäftsführer	Kollektivunterschrift zu zweien
0			Leuenberger, Matthias Andreas, von Melchnau, in Binningen	Geschäftsführer	Kollektivunterschrift zu zweien
0			Maurer, Patrik, deutscher Staatsangehöriger, in Winterthur	Geschäftsführer	Kollektivunterschrift zu zweien
0			Klee, Christian, von Diepfingen und Rüeggisberg, in Winchester (US)	Vorsitzender der Geschäftsführung	Kollektivunterschrift zu zweien
0			PricewaterhouseCoopers AG (CHE-151.657.932), in Winterthur	Revisionsstelle	
0	1		Leisner, Christian Valdemar Vinge, dänischer Staatsangehöriger, in Thalwil		Kollektivunterschrift zu zweien
0			Massa Mias, Regina, spanische Staatsangehörige, in Basel		Kollektivunterschrift zu zweien
0			Pfirter, Simone Doris, von Pratteln, in Pratteln		Kollektivunterschrift zu zweien
0	1		Steiner, Peter, von Schänis, in Altendorf		Kollektivunterschrift zu zweien
0	1		Tegenbos, Ellen Luc Angélique, von Münchenbuchsee, in Remetschwil		Kollektivunterschrift zu zweien

Basel, 26.05.2017 07:50 KO



Dieser Auszug aus dem kantonalen Handelsregister hat ohne die nebenstehende Originalbeglaubigung keine Gültigkeit. Er enthält alle gegenwärtig für diese Firma aktuellen Eintragungen sowie allfällig gestrichene Eintragungen. Auf besonderes Verlangen kann auch ein Auszug erstellt werden, der lediglich alle gegenwärtig aktuellen Eintragungen enthält.

Handelsregisteramt Basel-Stadt